At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
Low dose ADP101 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)
In Brief
A Phase 2 clinical trial evaluating Low dose ADP101, High dose ADP101, and 1 other intervention for Food Allergy. Completed, enrolled 73 participants across 15 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Allergy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartApr 2021
First PostedApr 2021
Primary CompletionNov 2022
Study CompletionDec 2022
TodayJul 2026
First PostedApr 23, 2021
Enrollment StartApr 20, 2021
Primary CompletionNov 22, 2022
Study CompletionDec 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.2 years ago
Interventions
Low dose ADP101biological
Active powder formulation
High dose ADP101biological
Active powder formulation.
Pooled Placebobiological
Placebo powder